Bristol-Myers adds to immuno-oncology portfolio

On July 5, 2016, Bristol-Myers Squibb (NASDAQ: BMY) acquired the privately-held, Sweden-based Cormorant Pharmaceuticals AB for $95 million. The driver behind this acquisition was gaining full rights to Cormorant’s HuMax-IL8 antibody program, which may result in an additional $425 million in development and regulatory milestone payments. Cormorant had acquired HuMax-IL8 from GenMab A/S in 2012 […]